JM2

JM2 (juxtamembrane 2) is a synthetic mimetic peptide derived from the juxtamembrane region of the connexin43 (Cx43) carboxy-terminus. It is designed to specifically disrupt the non-junctional interaction between Cx43 and microtubules, a complex that has been implicated in cancer cell plasticity, epithelial-mesenchymal transition (EMT), and the maintenance of cancer stem cells (CSCs). By inhibiting this interaction, JM2 limits the survival, proliferation, and migration of glioma stem cells (GSCs) and prevents metastasis in breast cancer models. Developed by researchers at Virginia Tech, JM2 has been studied in preclinical models of glioblastoma and metastatic breast cancer, often utilizing nanoparticle encapsulation (JM2-NPs) to enhance stability and delivery.

Other names

connexin43 mimetic peptideconnexin-43 mimetic peptideconnexin 43 mimetic peptideCx43 mimetic peptideCx-43 mimetic peptideCx 43 mimetic peptide